The two abnormal functions of the fusion protein that promote the invasion and migration of gastric cancer cells also partly explain the decreased survival rates and worse prognosis of patients with diffuse gastric cancer with the CLDN18-ARHGAP26 fusion compared with those without the CLDN18-ARHGAP26 fusion. This evidence concerns the gene ARHGAP26 and gastric cancer.